News

Hemanext Expands Commercial Footprint Through Strategic Partnership with OneBlood

Hemanext Inc., a leading innovator in technology for improving the quality of red blood cells for transfusion, announced a strategic production partnership with OneBlood, one of the nation’s largest independent blood centers, marking a significant milestone in Hemanext’s commercial expansion and accelerating adoption of Hemanext ONE® across the United States.

OneBlood is a blood establishment dedicated to saving lives by providing lifesaving products and services to more than 250 hospitals across Florida, Georgia, and the Carolinas. OneBlood serves approximately 7% of the United States national market, supplying more than 900,000 units of red blood cells annually. OneBlood will begin production at all three of its blood processing facilities located in Charlotte, North Carolina; St. Petersburg, Florida; and Orlando, Florida.

Cliff Numark, President and Chief Executive Officer of OneBlood stated, “We are grateful to further contribute to patient care through an innovative product, like Hemanext ONE. Innovation is a OneBlood core value, and we look forward to our partnership with Hemanext and saving even more lives.”

“This partnership with OneBlood represents a major step forward in expanding patient access to oxygen-controlled red blood cells using Hemanext ONE. OneBlood routinely provides innovative blood products throughout their network, and we are excited to bring yet another innovation to patients with OneBlood. Working with OneBlood and their hospital network strengthens our commercial presence in key U.S. healthcare markets by providing high quality red blood cells to patients who need them most.” stated Shane Ray, CEO of Hemanext.

About Hemanext
Hemanext Inc. is a privately held medical technology company based in Lexington, Massachusetts, focused on improving the quality, safety, efficacy, and cost of transfusion therapy. The company develops technologies designed to enable the storage of oxygen-controlled (hypoxic) red blood cells with the goal of improving transfusion outcomes for patients worldwide.

About OneBlood
OneBlood is a not-for-profit 501(c)(3) community asset responsible for providing safe, available and affordable blood to more than 250 hospital partners and their patients throughout Florida, North Carolina, South Carolina, Georgia and Alabama. OneBlood operates more than 90 donor centers and deploys nearly 250 Big Red Bus bloodmobiles throughout the southeastern United States for blood drives. To learn more about OneBlood visit www.oneblood.org.

About HEMANEXT ONE
Hemanext ONE® is a first-in-class disposable medical device designed to improve the quality of red blood cells for transfusion by removing oxygen and maintaining hypoxic storage conditions. The system is intended to process and store whole blood- or apheresis-derived leukocyte-reduced red blood cells collected in CP2D/AS-3 or apheresis-derived LR-RBC in ACD-A/AS-3.

Hemanext ONE has received marketing authorization from the U.S. Food and Drug Administration and is CE-marked for commercial distribution in the European Economic Area and the United Kingdom.

Hemanext Media Contact
Suzanna van Straaten
EMEA Commercial Lead & Head of Global Marketing
Suzanna.vanstraaten@hemanext.com
Mobile: +31 6 12 36 54 61

Previous

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us